Oncolytic viruses are genetically modified viruses that preferentially replicate in host cancer cells, leading to the production of new viruses and, ultimately, cell death. Currently, no oncolytic viruses that are able to kill only tumor cells while leaving normal cells intact are available. Using T-REx (Invitrogen, Carlsbad, CA) gene switch technology and a self-cleaving ribozyme, we have constructed a novel oncolytic HSV-1 recombinant, KTR27, whose replication can be tightly controlled and regulated by tetracycline in a dose-dependent manner. Infection of normal replicating cells as well as multiple human cancer cell types with KTR27 in the presence of tetracycline led to 1,000-to 250,000-fold-higher progeny virus production than in the absence of tetracycline, while little viral replication and virus-associated cytotoxicity was observed in infected growth-arrested normal human cells. We show that intratumoral inoculation with KTR27 markedly inhibits tumor growth in a xenograft model of human non-small-cell lung cancer in nude mice. It is shown further that replication of KTR27 in the inoculated tumors can be efficiently controlled by local codelivery of tetracycline to the target tumors at the time of KTR27 inoculation. Collectively, KTR27 possesses a unique pharmacological feature that can limit its replication to the targeted tumor microenvironment with localized tetracycline delivery, thus minimizing unwanted viral replication in distant tissues following local virotherapy. This regulatory mechanism would also allow the replication of the virus to be quickly shut down should adverse effects be detected.
Advances in cancer biology, together with a detailed understanding of the roles of host factors and virus-encoded gene products in controlling virus production in infected cells, have facilitated the use of some viruses as potential therapeutic agents against cancer (2, 24, 39) . Herpes simplex virus (HSV) possesses several unique properties as an oncolytic agent (2) . It has a short replication cycle (9 to 18 h) and can infect a broad range of cell types, leading to new virus replication and cell death. HSV encodes many nonessential genes that, when deleted, reduce the ability of the virus to replicate in nondividing normal cells. Because of its large genome, multiple therapeutic genes can be packaged into the genome of oncolytic recombinants.
The use of a replication-conditional strain of HSV-1 as an oncolytic agent was first reported for the treatment of malignant gliomas (29) . Since then, various efforts have been made in an attempt to broaden their therapeutic efficacy and increase the replication specificity of the virus in tumor cells (1, 3, 7, 8, 10, 11, 19, 20, 23, 26, 28, 30-32, 40, 46, 48) . Not surprisingly, however, deletion of genes that impair viral replication in normal cells also leads to a marked decrease in the oncolytic activity of the virus for the targeted tumor cells (1, 10, 19, 20, 37, 45) . Currently, no oncolytic viruses that are able to kill only tumor cells while leaving normal cells intact are available. Consequently, the therapeutic doses of existing oncolytic viruses are significantly restricted (2) . The availability of an oncolytic virus whose replication can be tightly controlled and adjusted pharmacologically in the tumor microenvironment would minimize the systemic cytotoxicity caused by disseminated virus following local oncolytic virotherapy (25) and thus maximize the treatment dose, resulting in increased therapeutic efficacy. This regulatory feature would also allow replication of the oncolytic virus to be quickly shut down should adverse effects be detected (2) .
There have been several studies focusing on developing regulatable replication-conditional virus or oncolytic virus for tumor therapy. Notably, two or three separated vectors have to be constructed (9, 16, 43, 54) . Employing the tetracycline repressor tetR and the full-length human cytomegalovirus (hCMV) major immediate-early (IE) promoter bearing two tandem tet operators downstream of the TATA element, we established a novel tetracycline-inducible gene expression system in mammalian cells (T-REx; Invitrogen, Carlsbad, CA) (51) and demonstrated that T-REx gene switch technology is fully functional in the context of a replication-defective HSV-1 genome (52) . Given that gene expression can be regulated in a highly sensitive manner following infection of cells with the T-REx-encoding replication-defective virus both in vitro and in vivo, we set out to explore the utility of T-REx gene switch technology in construction of a regulatable oncolytic HSV recombinant whose replication can be stringently controlled by tetracycline.
HSV replicates in epithelial cells and fibroblasts and establishes lifelong latent infection in neuronal cell bodies within the sensory ganglia of infected individuals. During productive infection, HSV genes fall into the following three major classes based on the temporal order of their expression: immediateearly (IE), early (E), and late (L) (41) . The HSV-1 viral proteins directly relevant to the current study are two IE regulatory proteins, ICP27 and ICP0. ICP27 is an essential viral IE protein that modifies and transports viral transcripts to the cytoplasm (42) . Although not essential for productive infection, ICP0 is required for efficient viral gene expression and replication at low multiplicities of infection (MOIs) in normal cells and efficient reactivation from latent infection (6, 22, 50) . Recent studies have revealed that ICP0 is needed to stimulate translation of viral mRNA in quiescent cells (47) and plays a key role in blocking IFN-induced inhibition of viral infection (13, 35, 36) . ICP0 also has E3 ubiquitin ligase activity and induces the disruption and degradation of ND10 proteins that have been implicated in controlling cell senescence and DNA repair (14) . Given that tumor cells are impaired in various cellular pathways, such as DNA repair, interferon signaling, and translation regulation (18, 33) , it is not surprising that ICP0 deletion mutants replicate more efficiently in cancer cells than in normal cells, particularly quiescent cells and terminally differentiated cells. The oncolytic potential of ICP0 mutants was first illustrated by Yao and Schaffer (50) , who showed that the plaque-forming efficiency of an ICP0 null mutant in human osteosarcoma cells (U2OS) is 100-to 200-fold higher than in nontumorigenic African green monkey kidney cells (Vero). The preferential ability of ICP0 mutants to replicate in selected types of cancer cells has been further explored in the recent study of Hummel et al. with an HSV-1 virus lacking both ICP0 and a HSV-1 virion-associated transactivator, VP16 (17) .
Here we describe the construction and characterization of a novel regulatable oncolytic HSV-1 recombinant, KTR27, which encodes the tetR gene controlled by the ICP0 promoter at the ICP0 locus and the essential ICP27 gene under the control of the tetO-bearing ICP27 promoter. Because ICP27 is a viral IE protein and only very low levels of ICP27 are needed for efficient viral replication in cell cultures (27, 44) , we inserted a self-cleaving ribozyme (53) into the 5Ј untranslated region of the ICP27 gene to reduce the accumulation of ICP27 prior to suppression of the tetO-bearing ICP27 promoter by de novo-synthesized tetR. We hypothesized that repression of the tetO-bearing ICP27 promoter by tetR concomitant with reduction in ICP27 protein synthesis by a self-cleaving ribozyme would greatly impair the ability of the virus to initiate productive infection in the absence of tetracycline, leading to the generation of a new class of HSV-1 recombinant whose replication can be controlled by the presence or absence of tetracycline. Indeed, we show that replication of KTR27 can be tightly regulated by tetracycline in various human tumor cells and normal replicating cells. Importantly, the combination of ICP0 deletion and downregulation of ICP27 expression by the self-cleaving ribozyme significantly restricts the replication of KTR27 in primary human cells compared with that of various tumor cells. KTR27 is avirulent following intratumoral and intracerebral inoculation in mice, whether they receive a standard diet or a doxycycline-containing diet. The potential use of this virus as an agent against cancers is demonstrated in a xenograft model of human lung cancer in nude mice.
MATERIALS AND METHODS
Plasmids. p27BS is an ICP27-expressing plasmid with flanking sequences 406 bp upstream of the ICP27 open reading frame and 461 bp downstream of the ICP27 poly(A) signal (kindly provided by P. A. Schaffer, Harvard Medical School). pTO-27, derived from p27BS, contains two tandem tet operators (5Ј-TC CCTATCAGTGATAGAGATCTCCCTATCAGTGATAGAGATCGCTGCA-3Ј) located 20 bp downstream of the last nucleotide of the TATAAGG element in the ICP27 promoter. Insertion of a DNA sequence containing the aforementioned tetO elements (underlined sequence above) at the EagI site downstream of the ICP27 TATA element in the described orientation generates a unique EagI site at the 5Ј end of the insert and a unique PstI site at the 3Ј end of the insert. Using lacZ as a reporter, we demonstrate that, like the tetO-bearing hCMV major IE promoter, the tetO-bearing ICP27 promoter can be sensitively regulated by tetracycline in the presence of tetR (data not shown).
pTO-RZ27, derived from pTO-27, contains a DNA sequence encoding a self-cleaving ribozyme, N107 (53) , flanked by 5Ј PstI and 3Ј AgeI restriction enzyme cleavage sites, inserted into the 5Ј untranslated region of the ICP27 coding sequence in pTO-27 at the PstI and AgeI sites. The presence of the tetO and N107 sequences in pTO-RZ27 was verified by DNA sequencing. Western blot analysis of cell extracts prepared from U2OS cells transfected with pTO-27, pTO-RZ27, and two additional constructs similar to pTO-RZ27 demonstrates that the presence of N107 in the 5Ј untranslated region of the ICP27 gene markedly reduced ICP27 expression in pTO-RZ27-transfected cells compared with cells transfected with pTO-27 (data not shown), consistent with the study of Yen et al. that insertion of N107 into the 5Ј untranslated region of the lacZ gene led to an approximately 100-fold reduction in ␤-galactosidase (␤-Gal) expression (53) .
Cells and viruses. The osteosarcoma cell line U2OS and the African green monkey kidney cell line (Vero) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (50) . U2OS cells express a cellular activity that can effectively complement the function of the HSV-1 IE regulatory protein ICP0 lacking in ICP0
Ϫ mutant viruses (50) . Primary human fibroblasts were grown in DMEM containing 10% FBS plus 1ϫ nonessential amino acids (Sigma, St. Louis, MO) (49) . R27 is an ICP27-expressing cell line derived from tetR-expressing U2OS cells (4) . R27 cells were grown in DMEM growth medium containing G418 (400 g/ml) and hygromycin B (50 g/ml). 7134 is an ICP0-null mutant in which both copies of the ICP0 coding sequence are replaced by the LacZ gene of Escherichia coli (6) . 7134 was propagated and assayed in U2OS cells (50) . K0R is an HSV-1 recombinant generated by recombinational replacement of the LacZ gene in 7134 with the DNA sequence encoding tetR (52) . K0R27-lacZ was derived from K0R in which the ICP27 coding sequence was replaced with the LacZ gene by homologous recombination using plasmid pf27-lacZ, constructed by replacing the ICP27 coding sequence in pBS27 with the LacZ gene under the control of the hCMV IE promoter (Yao et al., unpublished work). Replacement of the ICP27 gene with the lacZ gene in the ICP27 locus in K0R27-lacZ was verified by PCR analysis of 7134 and K0R27-lacZ viral DNA with a pair of ICP27 sequence-specific primers that flank the ICP27 gene according to the protocol described previously (52) (data not shown). K0R27-lacZ is replication incompetent in U2OS cells and was propagated and assayed in R27 cells.
SDS-PAGE and Western blot analysis. Sixty-millimeter dishes of Vero cells were infected at an MOI of 5 PFU/cell with 7134 or KTR27 in the absence and presence of tetracycline. Cell extracts were prepared at 4, 6, and 9 h postinfection as described previously (50) . Proteins in cell extracts were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes. Western blot analyses were performed (50) with monoclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) specific for HSV IE proteins ICP4 (sc-69809) and ICP27 (sc-17544).
Quantitative real-time reverse transcription-PCR. Sixty-millimeter dishes of Vero cells in triplicate were infected with 7134 or KTR27 at an MOI of 5 PFU/cell in the absence and presence of tetracycline at 2.5 g/ml. Cells were harvested at 6 h postinfection, and total RNA was extracted using the RNeasy Plus mini kit (Qiagen Sciences, Germantown, MD) and suspended in 100 l of RNase-free water. RNA (ϳ2 g) was converted into cDNA with a SuperScript III Platinum SYBR green one-step quantitative real-time reverse transcription-PCR (qRT-PCR) kit (Invitrogen Inc., Carlsbad, CA) with ICP27 primers (forward, 5Ј-GTCTGGCGGACATTAAGGACA-3Ј; reverse, 5Ј-TGGCCAGAATG ACAAACACG-3Ј) and primers specific for ␤-actin (forward, 5Ј-ACGAGGCC CAGAGCAAGAG-3Ј; reverse, 5Ј-TCTCCATGTCGTCCCAGTTG-3Ј) (21) on an Eppendorf Mastercycler gradient (Eppendorf North America, Inc., Westbury, NY). The amounts of ICP27 and ␤-actin cDNAs were determined by quantitative real-time PCR using the same ICP27 primers and ␤-actin primers in a 25-l SYBR green mixture containing 5 l of cDNA on an ABI Prism 7300 sequence detection system (Applied Biosystems, Foster City, CA). The real-time PCR analyses consisted of 95°C for 1 min followed by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. pTO-RZ27 plasmid DNA was used as a positive control and to generate a standard curve for the described ICP27 real-time PCRs. The amplified ICP27 cDNA products from individual infections were normalized with the ␤-actin cDNA products.
Mice and experimental tumors. Female BALB/c (nu/nu) mice 5 to 6 weeks of age were purchased from Charles River Laboratories (Cambridge, MA). Mice were housed in metal cages at four mice per cage and maintained on a 12-h light/dark cycle. Mice were allowed to acclimatize for 1 week prior to experimentation. Animal experiments were conducted according to the protocols approved by the Harvard Medical Area Standing Committee on Animals and the American Veterinary Medical association.
A subcutaneous (s.c.) xenograft model of human non-small-cell lung cancer was established by implanting 7.5 ϫ 10 6 H1299 cells in a volume of 100 l in the left and right flanks of female BALB/c nude mice (15) . Once palpable tumors had developed, mice were randomly divided into several different groups and received either a normal diet or a doxycycline-containing diet at 6 g/kg (Bio-Serv, Frenchtown, NJ). Three days later, tumors with a maximum diameter of 3 to 5 mm were inoculated with DMEM or KTR27 as previously indicated. Given that (i) the association equilibrium constant of doxycycline with tetR is 5-fold higher than that of tetracycline (12) and 0.1 g/ml of tetracycline is sufficient to fully release the repression of tetR on KTR27 replication (see Fig. 4 ), and (ii) the biological half-life of doxycycline is 18 to 22 h, we stopped feeding mice in the doxycycline-treated group a doxycycline-containing diet 16 to 18 h before the third KTR27 inoculation on day 7. Tumor volumes were quantified every third day using calipers and by using the formula
where L is length and W is width (15) . Data are presented as means Ϯ standard errors of the mean (SEM).
To examine the tetracycline-dependent replication of KTR27 in the tumor microenvironment following intratumoral inoculation, mice bearing the preestablished H1299 tumors with a maximum diameter of 6 to 8 mm were randomly divided into three groups and received two intratumoral injections of KTR27 in a volume of 50 l/injection at a dose of 1 ϫ 10 7 PFU/tumor. Mice in group 1 received KTR27 treatment with no doxycycline in the inoculation medium, while mice in group 2 were inoculated with KTR27 with medium containing 1 g doxycycline. Both groups received a normal diet. Mice in group 3 were given a doxycycline-containing diet ad libitum 1 day before KTR27 inoculation. Mice were euthanized on day 3 postinoculation. Each individual tumor was isolated, cut into 8 pieces, and suspended in DMEM. After freezing and thawing three times and homogenization (4), large cellular and tissue debris was removed by centrifugation at 14,000 ϫ g for 10 min. Virus titers in each individual supernatant were assayed on U2OS cell monolayers in the presence of tetracycline.
RESULTS
Construction of a tetracycline-regulatable HSV-1 recombinant, KTR27. K0R27-lacZ is a tetR-expressing HSV-1 recombinant with the LacZ gene under the control of the hCMV IE promoter in the ICP27 locus (Fig. 1) . To introduce the ICP27-encoding DNA element in pTO-RZ27 into the K0R27-lacZ genome, we transfected U2OS cells with linearized pTO-RZ27 DNA followed by K0R27-lacZ superinfection at an MOI of 5 PFU/cell. Progeny virus was harvested 18 h postinfection, and plaque assays were performed on U2OS cell monolayers in the presence of tetracycline and 5-bromo-4-chloro-3-indolyl-␤-Dgalactopyranoside (X-Gal) (52) . White plaques, indicating replacement of the LacZ gene by the ICP27 coding sequence of pTO-RZ27, were isolated and plaque purified four times on U2OS cell monolayers in the presence of tetracycline. KTR27 is a viral recombinant exhibiting ϳ1,050-fold-higher plaqueforming efficiency in the presence of tetracycline than in the absence of tetracycline in U2OS cells. Moreover, KTR27 replicates 300,000-fold more efficiently in U2OS cells than in Vero cells in the presence of tetracycline. Replacement of the LacZ gene by the ICP27 gene in the ICP27 locus in KTR27 was confirmed by PCR analysis (52) .
Control of KTR27 replication by tetracycline. To further assess the dependence of KTR27 replication on tetracycline, we infected Vero cells with KTR27 in the presence and absence of tetracycline and harvested infected cells at 24, 48, and 72 h postinfection ( Fig. 2A) . Infection of cells with KTR27 in the presence of tetracycline at the indicated time points led to increases in virus yields of ϳ2,600-fold, 39,000-fold, and 212,000-fold, respectively, compared with cells infected in the absence of tetracycline. No increase in virus yields was detected from 24 h to 72 h postinfection in the absence of tetra- cycline, indicating that replication of KTR27 can be stringently repressed in the absence of tetracycline in infected Vero cells. In addition to the described experiment, we also assessed the replication efficiency of KTR27 at MOIs of 3 and 10 PFU/cell.
The results showed that yields of KTR27 at 24 h postinfection in cells infected in the presence of tetracycline were ϳ2,500-and 7,800-fold higher than that in cells infected in the absence of tetracycline, respectively (data not shown).
The Western blot analysis and quantitative real-time RT-PCR results presented in Fig. 2B and C indicate that the observed impairment in the replication efficiency of KTR27 in the absence of tetracycline is the direct result of inefficient expression of ICP27. As shown in Fig. 2B , while ICP27 can be readily detected in KTR27-infected cells in the presence of tetracycline, little ICP27 was expressed in KTR27-infected cells in the absence of tetracycline, particularly at 4 h postinfection. The same finding was also observed when the infected cells were harvested at 16 h postinfection (data not shown). Given that similar levels of ICP4 were detected among cells infected with 7134 and KTR27, and that repression of the tetO-bearing hCMV major immediate-early promoter by tetR can be completely abolished by tetracycline and insertion of the same tetO sequence downstream of the TATA element has little effect on the promoter activity of the hCMV major immediate-early promoter (51), the markedly higher level of ICP27 detected in 7134-infected cells than in cells infected with KTR27 in the presence of tetracycline suggests that insertion of the ribozyme N107 in the 5Ј untranslated region of ICP27 in KTR27 reduces expression of ICP27. Consistent with the Western blot results, results of quantitative real-time RT-PCR analyses shown in Fig. 2C reveal that levels of ICP27 mRNA in KTR27-infected cells (T ϩ ) are 4-fold lower than in cells infected with 7134 (P ϭ 0.05; Student's t tests). A 36-fold-lower level of ICP27 mRNA is detected in cells infected with KTR27 in the absence of tetracycline than the presence of tetracycline (P ϭ 0.03), demonstrating that transcription of ICP27 from the tetO-bearing ICP27 promoter is effectively repressed by tetR in the absence of tetracycline.
To directly investigate the impact of reduced ICP27 expression on KTR27 viral replication, we infected Vero cells with 7134 or KTR27 in the presence of tetracycline at MOIs of 0.1 and 1 PFU/cell, respectively. PFU/cell compared with 7134 infection. Thus, compared with ICP0 deletion mutants (6), reduction of ICP27 expression in the absence of ICP0 further restricts virus replication at a low multiplicity of infection.
Tetracycline dose-dependent replication of KTR27 in Vero cells is illustrated in Fig. 4 . Yield of KTR27 reached a 72-h maximum of 1 ϫ 10 6 PFU/ml at a tetracycline concentration of 0.1 g/ml, which is ϳ250,000-fold greater than the yield achieved without tetracycline (ϳ4 PFU/ml).
Tetracycline-dependent replication of KTR27 in cultured human tumor cells and primary cells. Having demonstrated that production of KTR27 can be tightly controlled by tetracycline in Vero cells, we asked whether a similar degree of control of KTR27 replication could be achieved in human tumor cells. As shown in Fig. 5A , infection of human tumor cell lines, such as prostate, lung, pancreatic, and breast tumors in the presence of tetracycline led to ϳ1,000-to 25,000-foldhigher viral yields than in the absence of tetracycline.
To examine the ability of KTR27 to replicate in dividing normal human fibroblasts as well as nondividing human fibroblasts, primary human fibroblasts were grown in either normal growth medium or were serum starved for 42 h as previously described (5). The results in Fig. 5B demonstrate that, compared with various human tumor cells, replication of KTR27 in normal primary human breast fibroblasts is severely impaired. No KTR27 virus was detected in infected normal primary human breast fibroblasts in the absence of tetracycline whether they had been grown in normal growth medium or were growth arrested following serum starvation. The yields of KTR27 in primary human breast fibroblasts were further restricted in growth-arrested primary human breast fibroblasts (116 PFU/ ml) compared to cells grown in normal growth medium (2,390 PFU/ml).
To directly compare the replication efficiency and induced cytotoxicity of KTR27 in tumor and normal cells, we infected human breast cancer cells, MCF7, and normal primary human breast fibroblasts that were either cultured with normal growth medium or underwent serum starvation in the presence of tetracycline (Fig. 6) . Yields of KTR27 at 72 h postinfection in infected MCF7 cells were about 4,500-fold higher than those in normal human breast fibroblasts growth arrested by serum starvation and about 530-fold higher than those in human fibroblasts grown in normal growth medium (Fig. 6A) . Infection of growth-arrested human breast fibroblasts with KTR27 induced little or no cytotoxicity in the infected cells, while ϳ98.5% of infected MCF7 cells were nonviable compared with the mock-infected control (Fig. 6B) . Figure 6C shows representative morphological views of mock-infected and KTR27-infected MCF7 cells and KTR27-infected normal human fibroblasts, described in on November 2, 2017 by guest http://jvi.asm.org/ cells remaining morphologically similar to the mock-infected MCF7 cells, little or no phenotypic differences were detected between infected and mock-infected normal human fibroblasts. This observation suggests that the cytotoxicity detected in KTR27-infected proliferating primary fibroblasts (Fig. 6B) was caused primarily by abortive replication of the input KTR27 viruses. Collectively, the results presented in Fig. 5 and 6 demonstrate that the ability of KTR27 to replicate in and kill normal primary human fibroblasts is significantly reduced in both the presence and absence of tetracycline compared with various human tumor cells. Prevention of growth of preestablished human non-smallcell lung cancer by KTR27 in immunodeficient mice. H1299 cells were implanted s.c. in the left and right flanks of female BALB/c (nu/nu) mice. When palpable tumors had developed, mice were randomly divided intro three groups and inoculated with DMEM or KTR27 at a dose of 1 ϫ 10 7 PFU/tumor (Fig.  7A) . While tumors inoculated with DMEM grew more than 40-fold during the 24-day follow-up, those inoculated with KTR27 grew less than 3-fold. Thus, intratumoral inoculation of preexisting non-small-cell lung tumors with KTR27 significantly inhibited tumor growth compared with DMEM-treated 6 human lung cancer cells (H1299) in a volume of 100 l on the left and right flanks. Once tumors were palpable, mice were randomly divided into three groups, and one group was started on a doxycycline-containing diet. Three days later, each tumor with a diameter of 3 to 5 mm was injected with 50 l of DMEM or KTR27 at a dose of 1 ϫ 10 7 PFU. Tumors received the same inoculation on days 3 and 7. For the group of mice treated with doxycycline, the special diet of doxycycline was discontinued 6 days after the first virus inoculation. Tumor volumes were quantified every third day for 24 days and are presented as means Ϯ SEM. (B) In vivo regulation of KTR27 replication by doxycycline in the preestablished tumors. Female BALB/c (nu/nu) mice were implanted with H1299 cells as described. When subcutaneous tumors reached a maximum diameter of 6 to 8 mm, mice were divided into three groups and received two intratumoral injections of KTR27 in a volume of 50 l/injection at a dose of 1 ϫ 10 7 PFU/tumor. Mice in group 1 received no doxycycline treatment (T Ϫ ). Group 2 mice received 1 g of doxycycline at the time of KTR27 inoculation (local), and mice in group 3 received systemic doxycycline treatment through their diet. Mice were euthanized on day 3 postinoculation, and virus yields in the harvested tumors were plaque assayed on U2OS cell monolayers in the presence of tetracycline. Virus titers in individual tumors from different groups of mice are presented as means Ϯ SEM. controls (P Ͻ 0.0015; unpaired t test). Inhibition of tumor growth by KTR27 was significantly more effective in mice receiving a doxycycline diet than in mice receiving a standard rodent diet without doxycycline (P ϭ 0.003; unpaired t test). No cytotoxicity or signs of herpetic infection were observed in the surrounding normal tissue following intratumoral injection of KTR27 in tetracycline-fed mice.
Experiments presented in Fig. 7B demonstrate that the observed inhibitory effect of KTR27 on tumor growth correlates directly to the tetracycline-dependent replication of KTR27 in the inoculated tumor microenvironment. Yield of KTR27 in the inoculated tumors of mice fed a doxycycline diet was 615-fold greater than that in mice receiving a normal diet (P Ͻ 0.0001; unpaired t test) on day 3 postinoculation. Replication of KTR27 can also be sufficiently controlled by local delivery of doxycycline (1 g) at the time of intratumoral inoculation of KTR27, yielding ϳ100-fold-higher KTR27 synthesis than that in non-doxycycline-treated controls (P Ͻ 0.001; unpaired t test).
Neurovirulence of KTR27. There is a fine balance in designing clinically effective oncolytic HSV recombinants that possess sufficient replicating ability in tumor cells to exert its oncolytic effect and yet cause little or no neurovirulence. The safety of KTR27 in potential clinical applications was thus further evaluated by intracerebral inoculation of groups of mice receiving either a doxycycline diet or a standard rodent diet at a dose of 1 ϫ 10 7 PFU/mouse (Fig. 8) . As controls, groups of mice were also inoculated with DMEM, 7134 at the same dose, or wildtype HSV-1 KOS at a dose of 1 ϫ 10 4 PFU/mouse. Morbidity and mortality were monitored for 35 days. Like inoculation of mice with DMEM, intracerebral inoculation of mice with KTR27 caused no signs of neurovirulence during a 35-dayperiod follow-up, whether or not mice had been fed doxycycline. This result is in sharp contrast to mice inoculated with KOS and the same dose of 7134, in which 6 out of 8 mice died by day 6 post-intracerebral inoculation and all inoculated mice exhibited signs of central nervous system (CNS) illness commonly associated with HSV-1 infection, including roughened fur, hunched posture, ataxia, and anorexia. In light of the demonstration that the doxycycline concentration in the brains of mice receiving the doxycycline-containing diet can efficiently release the tetR-mediated repression of gene expression following intracerebral inoculation of the T-REx-encoding, replication-defective HSV-1 recombinant virus (52) , the study indicates that the observed avirulence of KTR27 in mice receiving a doxycycline-containing diet is primarily the result of impairment in the ability of KTR27 to replicate in the mouse brain.
DISCUSSION
We have developed a new class of oncolytic HSV recombinants, exemplified by KTR27, whose replication can be tightly and sensitively regulated by tetracycline in both tumor cells and normal-replicating cells. KTR27 encodes two copies of the tetR gene under the control of the ICP0 promoter, while the essential ICP27 gene is controlled by the tetO-bearing ICP27 promoter and a self-cleaving ribozyme in the 5Ј untranslated region of the ICP27 coding sequence. Because the ICP0 promoter is a strong HSV-1 IE promoter whose activity is markedly enhanced by the virion-associated transactivator VP16, its use allows high and immediate-early expression of tetR following entry of the virus into the cell. We show that infection of cells with KTR27 in the presence of tetracycline leads to considerably higher levels of ICP27 expression than that of cells infected in the absence of tetracycline (Fig. 2B and C) , and impairment in ICP27 expression by KTR27 significantly affects the ability of KTR27 to replicate at a low multiplicity of infection (Fig. 3) .
We detected an approximately 250,000-fold tetracycline-dependent KTR27 replication in Vero cells and demonstrated that the degree of KTR27 replication can be sensitively adjusted by tetracycline in a dose-dependent manner. The highly effective tetracycline-dependent replication of KTR27 has also been demonstrated in cancer cell lines from human breast, lung, prostate, and pancreatic tumors (Fig. 5) . The observed differences in tetracycline-dependent viral replication of KTR27 in the tested tumor cell lines are likely due in part to the variation in the efficiency of the T-REx gene switch in regulating gene expression in different cells (51, 52) , particularly considering that in KTR27, expression of tetR is controlled by the HSV-1 ICP0 promoter while ICP27 is expressed by the tetO-bearing ICP27 promoter.
To explore the possible clinical applications of KTR27 in brain tumor therapy, we recently infected human glioblastoma U-87MG cells with KTR27 and observed a close to 375,000-fold tet-dependent replication of KTR27 (Spielmann and Yao, unpublished data), indicating the potential of KTR27 for lysis of multiple types of tumors. Because the efficiency of KTR27 replication can be regulated with different doses of tetracycline, it is reasonable to believe that the in situ oncolytic activity of KTR27 can be adjusted similarly by varying the amount of tetracycline in the tumor microenvironment. Thus, KTR27 also processes a regulatory feature that could limit the potential overload of progeny viruses in the targeted tumor microenvironment following virotherapy.
The preferential replication of KTR27 in human tumor cells over normal primary human cells is demonstrated in experiments shown in Fig. 5 and 6 . Specifically, replication of KTR27 FIG. 8 . KTR27 is avirulent after intracerebral inoculation. Female BALB/c mice 4 to 6 weeks old were randomly assigned to five groups of 8 mice each. Groups of mice were fed either a normal diet or a diet containing doxycycline (T ϩ ). After 3 days of feeding, mice were anesthetized with sodium pentobarbital and inoculated with either DMEM, 7134, or KTR27 through intracerebral injection into the left frontal lobe of the brain in a volume of 20 l (1 ϫ 10 7 PFU) at a depth of 4.5 mm. As a control, a group of mice were also received an intracerebral injection of wild-type HSV-1 KOS at 1 ϫ 10 4 PFU/mouse in a similar fashion. Mice were examined for signs and symptoms of illness for 35 days after KTR27 inoculation.
VOL. 84, 2010
A REGULATABLE ONCOLYTIC VIRUS 8169
on November 2, 2017 by guest http://jvi.asm.org/ in primary human fibroblasts is markedly reduced compared with that of various human tumor cells (Fig. 5) , and the yield of KTR27 in human breast cancer cells (MCF7) is ϳ4,500-fold higher than that in growth-arrested normal human breast fibroblasts (Fig. 6 ). These results demonstrate clearly that cytotoxicity and the ability of KTR27 to initiate productive viral replication in normal primary cells are significantly impaired even in the presence of tetracycline. We detected no KTR27 replication in normal human breast fibroblasts in the absence of tetracycline (Fig. 5B) .
To test the oncolytic effect of KTR27 on established tumors, we utilized the xenograft model of human non-small-cell lung cancer in nude BALB/c mice. In these tests, intratumoral inoculation of KTR27 in doxycycline-treated mice led to a 14-fold reduction in overall tumor growth compared with the DMEM-treated control (Fig. 7A) . The oncolytic activity of KTR27 was significantly compromised when the same inoculation was performed in mice fed a normal non-doxycyclinecontaining diet, consistent with the observed impairment in KTR27 replication in the inoculated H1299 tumors in the absence of tetracycline (Fig. 7B) . Yields of KTR27 per tumor were on average ϳ601,000 PFU on day 3 post-intratumoral inoculation in mice fed a doxycycline diet compared to 976 PFU in mice fed a normal diet. An average of ϳ96,200 PFU/ tumor of KTR27 was detected in mice that received an intratumoral injection of 1 g doxycycline at the time of KTR27 inoculation. These results show that de novo replication of KTR27 in the inoculated tumors can be effectively controlled by systemic tetracycline treatment (through a doxycycline diet) or by local intratumoral injection of doxycycline-containing KTR27 viral inocula. We detected no infectious KTR27 in blood collected from mice in any group on day 3 postinoculation. Moreover, intrafootpad injection of the same dose of KTR27 in nude mice fed a doxycycline diet yielded no detectable KTR27 in the targeted footpad tissues harvested on day 3 postinjection (data not shown), demonstrating further that the absence of ICP0 in conjunction with reduced ICP27 expression greatly impairs the replication of KTR27 in quiescent cells even in the presence of tetracycline. This finding is consistent with the observation that (i) intratumoral injection of KTR27 produced no toxic effects or signs of herpetic infection in surrounding normal tissue, whether in mice receiving a doxycycline-diet or mice fed a normal diet, and (ii) KTR27 is avirulent following intracerebral inoculation of mice at a dose of 1 ϫ 10 7 PFU/mouse (Fig. 8) . Collectively, we demonstrate that KTR27 is a safe and effective therapy in the treatment of non-small-cell lung cancer in a mouse xenograft model. Whether KTR27 would be equally effective against small-cell lung cancer or non-small-cell lung cancer xenografts derived from other non-small-cell lung cancer lines remains to be determined.
Lastly, it is worth noting that although intratumoral delivery of doxycycline led to a marked increase in de novo viral synthesis in the targeted tumor compared with virotherapy with no doxycycline treatment, the yield of KTR27 in the inoculated tumors following local delivery of doxycycline on day 3 postinoculation was ϳ6-fold less than that of mice fed a doxycycline diet (Fig. 7B) . It is thus conceivable that intratumoral replication efficiency of KTR27 can be improved by rational designs of biodegradable slow-release doxycycline-containing nanoparticles or microparticles, which can be codelivered to the targeted tumor at the time of KTR27 virotherapy (34, 38) . Such an optimized slow-release vehicle should provide a localized and prolonged therapeutic range of doxycycline/tetracycline in the tumor microenvironment while keeping systemic concentrations below the threshold required for de novo replication of disseminated viruses in nontargeted distant tissues and organs, leading to minimized systemic toxicity following local virotherapy.
